Results 31 to 40 of about 1,995 (245)

Segurança e Eficácia da Vacina Qdenga® (TAK-003) em Crianças de Até 12 anos: Uma Revisão Sistemática [PDF]

Brazilian Journal of Implantology and Health Sciences
Introduction: Dengue, a viral disease transmitted by the Aedes aegypti mosquito. poses a significant challenge to public health, especially in Brazil, where epidemics occur.
Barbosa de Figueiredo Medeiros, Luiz Antônio, de Almeida Pinto Júnior, Erinaldo, Formiga da Silva, Karolainy, Izadora de Caldas Francelino, Maria, Jorge Rebouças Júnior, Henrique, Luísa Moreira Barreiro de Araújo, Ana, Maria Oliveira Bitencourt Nóbrega, Bárbara, Matheus Formiga Farias, Lucas, Medeiros da Nóbrega, Neidivânia, Medeiros, Gabriel dos Santos, Mendes Dantas, Ruthy Anny, Nunes Alves de Sousa, Milena, Suassuna de Aquino, Ana Caroliny   +12 more
core   +3 more sources

Dengue Vaccine Development and Deployment into Routine Immunization [PDF]

Vaccines
Dengue has emerged as a significant global health threat. Despite decades of research, only two dengue vaccines—CYD-TDV (Dengvaxia) and TAK-003 (Qdenga)—have been licensed to date, with limited implementation.
Annelies Wilder-Smith, Thomas Cherian, Joachim Hombach   +2 more
doaj   +2 more sources

The pre- and post-COVID-19 pandemic dengue fever patterns in southeastern coastal China in 2019 and 2024: molecular evolution and strain replacement [PDF]

Frontiers in Microbiology
BackgroundThe evolutionary dynamics of dengue virus type 1 (DENV-1) in non-endemic settings such as southeastern coastal China where outbreaks predominantly stem from imported cases, remains insufficiently defined, particularly in relation to lineage ...
Tianran Zhang, Yaqi Shi, Leyi Zhang, Jian Wang, Chengchao Yu, Binbin Lv, Sisi Wu, Yiru Huang, Xuewei Liu, Hupiao Dai, Mingshi Zhou, Yanjuan Liao, Wei Wang, Guankai Lin   +13 more
doaj   +2 more sources

Advancing dengue vaccine development: Challenges, innovations, and the path toward global protection [PDF]

Pediatric Investigation
Dengue fever remains a significant global health threat, placing nearly half of the world's population at risk. Despite decades of research, developing an effective dengue vaccine continues to face multiple challenges, including antibody‐dependent ...
Ran Wang, Bridget Kim, Hridesh Mishra, Kevin C. Kain   +3 more
doaj   +2 more sources

Estimated Efficacy of TAK-003 Against Asymptomatic Dengue Infection in Children and Adolescents Participating in the DEN-301 Trial in Asia Pacific and Latin America [PDF]

Journal of Infectious Diseases
Edson Duarte Moreira, Ana Lucia Allo Lyrio De Oliveira, Veerachai Watanaveeradej   +2 more
exaly   +2 more sources

GRADE 3 SOLICITED AND UNSOLICITED ADVERSE EVENTS (AES) FOLLOWING VACCINATION WITH TAKEDA'S TETRAVALENT DENGUE VACCINE CANDIDATE (TAK-003)

International Journal of Infectious Diseases, 2023
Intro: An ongoing, long-term phase 3 trial (NCT02747927) in eight dengue- endemic countries is evaluating Takeda's dengue vaccine candidate, TAK-003.
E. Ismail, V. Tricou, N. Folschweiller, E. Lloyd, M. Rauscher, S. Biswal   +5 more
doaj   +1 more source

97. Tetravalent Dengue Vaccine (TAK-003) Development Program: A Bird’s Eye View [PDF]

Open Forum Infect Dis, 2021
Abstract Background Dengue fever is a mosquito-borne viral disease endemic in 128 countries. An unmet clinical need remains for an effective vaccine that can be used more broadly than the vaccine presently available.
Tricou V, Biswal S, Liu M, Patel S, Zent O, Rauscher M, Perez G, Kandeil W, Folschweiller N.   +8 more
europepmc   +3 more sources

Baseline Anti-Dengue IgG Seroprevalence in a Pediatric Brazilian Population Before TAK-003 Vaccination. [PDF]

Am J Trop Med Hyg
ABSTRACT. Dengue remains a major public health challenge in Brazil, with recurrent outbreaks placing a strain on healthcare systems. The TAK-003 vaccine offers a promising control strategy, particularly for children. This cross-sectional study evaluated the seroprevalence of anti-dengue IgG in 643 children and adolescents aged 4–16 ...
Bortuluzi AMM, Dos Santos PCP, Anschau LCK, da Silva Santos A, Tsuha D, Santos DS, de Souza WM, Oliveira RD, Croda J.   +8 more
europepmc   +3 more sources

Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City

Revista Panamericana de Salud Pública, 2021
Objective. To describe the immunogenicity and safety of a tetravalent dengue vaccine (TAK-003) in healthy adolescents living in Mexico City, an area considered non-endemic for dengue (NCT03341637). Methods. Participants aged 12–17 years were randomized 3:
Shibadas Biswal, Jorge Fernando Mendez Galvan, Mercedes Macias Parra, Juan-Francisco Galan-Herrera, Monica Belisa Carrascal Rodriguez, Esteban Patricio Rodriguez Bueno, Manja Brose, Martina Rauscher, Inge LeFevre, Derek Wallace, Astrid Borkowski   +10 more
doaj   +1 more source

EFFICACY AND SAFETY OF TAKEDA'S TETRAVALENT DENGUE VACCINE CANDIDATE (TAK-003) AFTER 4.5 YEARS OF FOLLOW-UP: RESULTS FROM PARTICIPANTS IN ASIA

International Journal of Infectious Diseases, 2023
Intro: An ongoing, long-term, phase 3 trial (NCT02747927) in eight dengueendemic countries across Asia and Latin America is evaluating the efficacy, safety, and immunogenicity of Takeda's tetravalent dengue vaccine candidate, TAK-003.
A. Green, S. Biswal, E. Lloyd, V. Tricou, N. Folschweiller   +4 more
doaj   +1 more source